Health-care companies rose as deal activity in the sector intensified.

Health-care companies ticked down as deal activity offset fears about generic competition for one key category of drugs.

GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.